CA2981188C - Azophenols as erg oncogene inhibitors - Google Patents
Azophenols as erg oncogene inhibitors Download PDFInfo
- Publication number
- CA2981188C CA2981188C CA2981188A CA2981188A CA2981188C CA 2981188 C CA2981188 C CA 2981188C CA 2981188 A CA2981188 A CA 2981188A CA 2981188 A CA2981188 A CA 2981188A CA 2981188 C CA2981188 C CA 2981188C
- Authority
- CA
- Canada
- Prior art keywords
- erg
- compound
- pharmaceutically acceptable
- acceptable salt
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/04—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216839P | 2015-09-10 | 2015-09-10 | |
| US62/216,839 | 2015-09-10 | ||
| PCT/US2016/051098 WO2017044844A1 (en) | 2015-09-10 | 2016-09-09 | Azophenols as erg oncogene inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2981188A1 CA2981188A1 (en) | 2017-03-16 |
| CA2981188C true CA2981188C (en) | 2024-05-28 |
Family
ID=58240304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2981188A Active CA2981188C (en) | 2015-09-10 | 2016-09-09 | Azophenols as erg oncogene inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10238639B2 (enExample) |
| EP (1) | EP3347001B1 (enExample) |
| JP (1) | JP6865174B2 (enExample) |
| AU (1) | AU2016319111B2 (enExample) |
| CA (1) | CA2981188C (enExample) |
| WO (1) | WO2017044844A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6865174B2 (ja) | 2015-09-10 | 2021-04-28 | ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド | Ｅｒｇ癌遺伝子阻害剤としてのアゾフェノール |
| CA3179323A1 (en) * | 2020-06-19 | 2021-12-23 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Erg oncogene inhibitors |
| CN113616645A (zh) * | 2021-08-27 | 2021-11-09 | 深圳先进技术研究院 | 一种噻唑基重氮萘酚类化合物在制备治疗恶性脑胶质瘤药物中的应用 |
| WO2023097119A2 (en) * | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0738075B2 (ja) * | 1986-12-23 | 1995-04-26 | 住友化学工業株式会社 | 新規なフオトレジスト組成物 |
| US6168843B1 (en) * | 1996-12-27 | 2001-01-02 | Tdk Corporation | Optical recording medium |
| WO2010101994A2 (en) * | 2009-03-03 | 2010-09-10 | The Regents Of The University Of Michigan | Gene fusion targeted therapy |
| EP3052655B1 (en) | 2013-09-30 | 2018-11-07 | Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center | Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed |
| JP6865174B2 (ja) | 2015-09-10 | 2021-04-28 | ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド | Ｅｒｇ癌遺伝子阻害剤としてのアゾフェノール |
-
2016
- 2016-09-09 JP JP2017550884A patent/JP6865174B2/ja active Active
- 2016-09-09 US US15/561,626 patent/US10238639B2/en active Active
- 2016-09-09 CA CA2981188A patent/CA2981188C/en active Active
- 2016-09-09 WO PCT/US2016/051098 patent/WO2017044844A1/en not_active Ceased
- 2016-09-09 AU AU2016319111A patent/AU2016319111B2/en not_active Ceased
- 2016-09-09 EP EP16845184.7A patent/EP3347001B1/en active Active
-
2019
- 2019-02-15 US US16/277,410 patent/US20190336485A1/en not_active Abandoned
-
2021
- 2021-01-26 US US17/158,930 patent/US11648239B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017044844A1 (en) | 2017-03-16 |
| AU2016319111A1 (en) | 2017-10-19 |
| AU2016319111B2 (en) | 2021-05-06 |
| EP3347001B1 (en) | 2023-07-26 |
| JP6865174B2 (ja) | 2021-04-28 |
| US10238639B2 (en) | 2019-03-26 |
| US20180169074A1 (en) | 2018-06-21 |
| US20210299106A1 (en) | 2021-09-30 |
| CA2981188A1 (en) | 2017-03-16 |
| US11648239B2 (en) | 2023-05-16 |
| JP2018526320A (ja) | 2018-09-13 |
| EP3347001A1 (en) | 2018-07-18 |
| HK1258415A1 (en) | 2019-11-08 |
| EP3347001A4 (en) | 2019-05-08 |
| US20190336485A1 (en) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11648239B2 (en) | Azophenols as ERG oncogene inhibitors | |
| Chang et al. | 4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype | |
| Avdieiev et al. | Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds | |
| Wedel et al. | Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells | |
| CA2846272A1 (en) | Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone | |
| AU2015229379B2 (en) | Novel inhibitors for ERG oncogene positive cancers | |
| CN107820426A (zh) | 用于治疗癌症的方法 | |
| HK1258415B (en) | Azophenols as erg oncogene inhibitors | |
| EP3893861B1 (en) | Treatment and prevention of glioblastoma | |
| KR101599259B1 (ko) | 혈관 신생작용 관련 질환 치료를 위한 HIF-1α 저해 화합물 | |
| EP3664788A1 (en) | Compounds for treating von hippel-lindau disease | |
| Botella et al. | Compounds for treating von Hippel-Lindau disease | |
| Osherovich | Grasping the Hedgehog | |
| Liu et al. | Genetic alterations in the PI3K/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mTOR | |
| Xiao | Discovery of Novel Tubulin Polymerization Inhibitors and Survivin Inhibitors as Potential Anticancer Agents | |
| KR20150101693A (ko) | HBx의 발현 억제제를 유효성분으로 포함하는 간암 전이 억제용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210310 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240830 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240830 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240830 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251222 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260420 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260713 |